Latent TB Infection Testing Market Size, Share, Growth, Trends and Industry Analysis, By Type (Mantoux Test / Tuberculin Skin Test (TST), Interferon-Gamma Release Assay (IGRA)), By Application (Hospitals, Public and Student Health, Physician Offices and Clinics, Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

LATENT TB INFECTION TESTING MARKET OVERVIEW

Starting at USD 1.82 Billion in 2026, the global Latent TB Infection Testing Market is set to witness notable growth. By 2035, it is projected to reach USD 2.89 Billion. The market is expected to expand at a CAGR of 5.3% throughout the forecast period from 2026 to 2035.

The Latent TB Infection Testing Market is expanding due to increasing tuberculosis prevention programs, rising screening activities, and growing adoption of advanced diagnostic technologies. Latent tuberculosis infection testing identifies individuals infected with Mycobacterium tuberculosis without active disease symptoms. More than 10 million tuberculosis cases are estimated globally each year, while approximately 1.7 billion people are affected by latent TB infection worldwide. Diagnostic methods such as Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (IGRA) are widely used across healthcare systems. IGRA testing is increasingly preferred in developed markets because it provides results within 24 hours and requires fewer patient visits. The Latent TB Infection Testing Market Report highlights increasing demand for accurate screening among healthcare workers, immigrants, immunocompromised populations, and high-risk communities. The Latent TB Infection Testing Market Analysis indicates that government screening initiatives and improved diagnostic infrastructure are major factors influencing market expansion.

The United States represents a significant market for latent TB infection testing due to strong public health screening programs and continuous monitoring of high-risk populations. The country reports approximately 9,000 to 10,000 tuberculosis cases annually, with latent TB infection affecting nearly 13 million residents. Healthcare workers, immigrants from high TB-burden countries, correctional facility populations, and immunosuppressed patients represent major testing groups. Approximately 80% of tuberculosis cases in the United States originate from reactivation of latent infections, increasing demand for early identification. IGRA tests account for nearly 60% of latent TB diagnostic testing in many U.S. healthcare settings due to improved specificity and reduced cross-reactivity compared with traditional methods. Hospitals and public health departments conduct millions of screening procedures annually, supporting the Latent TB Infection Testing Industry Report and increasing adoption of advanced diagnostic platforms.

KEY FINDINGS

LATEST TRENDS

Rise of Point-of-Care Solutions Transforming Latent TB Testing for Accessibility

The Latent TB Infection Testing Market Trends demonstrate increasing adoption of highly specific diagnostic methods, particularly Interferon-Gamma Release Assay (IGRA) technologies. IGRA testing is gaining preference because it requires only 1 patient visit, compared with traditional Tuberculin Skin Test methods that generally require a follow-up visit after 48 to 72 hours. Approximately 55% of healthcare facilities in developed countries are adopting IGRA-based testing due to improved operational efficiency and reduced patient inconvenience. Automation is becoming a major trend in the Latent TB Infection Testing Market Forecast, with approximately 40% of modern laboratories integrating automated sample processing and digital result management systems. These technologies improve workflow efficiency and reduce manual errors by nearly 25%. Healthcare organizations are increasingly implementing electronic reporting systems that allow faster communication between laboratories, physicians, and public health authorities.

Another important trend is increasing screening among vulnerable populations. Approximately 20% of latent TB testing demand comes from healthcare workers, while immigrants and individuals from high-risk regions contribute nearly 35% of screening activities. Immunocompromised populations, including patients receiving immune-suppressing therapies, represent approximately 15% of testing demand.

Download Free Sample to learn more about this report

LATENT TB INFECTION TESTING MARKET SEGMENTATION

By Type

Depending on latent TB infection testing market given are types: Mantoux Test / Tuberculin Skin Test (TST), Interferon-Gamma Release Assay (IGRA).

• Mantoux Test / Tuberculin Skin Test (TST): The Mantoux Test / Tuberculin Skin Test (TST) remains one of the most widely used methods in the Latent TB Infection Testing Market, accounting for approximately 40% of global testing procedures. The method involves injecting purified protein derivative (PPD) under the skin and measuring immune response after 48 to 72 hours. TST continues to be preferred in regions with limited laboratory infrastructure because it requires minimal equipment and lower operational complexity. Approximately 70% of large-scale tuberculosis screening campaigns in low-resource regions utilize TST because of its cost efficiency and simplified implementation. Public health programs, schools, prisons, and occupational health screening centers frequently use this method for identifying individuals exposed to tuberculosis bacteria. More than 100 countries continue incorporating TST into national tuberculosis control strategies.

• Interferon-Gamma Release Assay (IGRA): The Interferon-Gamma Release Assay (IGRA) segment represents the leading category in the Latent TB Infection Testing Market Share, accounting for approximately 60% of global testing adoption. IGRA tests measure immune response by detecting interferon-gamma release after exposure of blood samples to tuberculosis-specific antigens. These tests provide results within approximately 24 hours, reducing patient follow-up requirements compared with traditional skin testing. IGRA adoption is particularly strong in developed healthcare systems, where approximately 65% of hospitals prefer IGRA-based testing due to improved specificity and operational efficiency. The technology is widely used among healthcare workers, immunocompromised patients, transplant candidates, and individuals from high-risk tuberculosis regions.

By Application

The market is divided into Hospitals, Public and Student Health, Physician Offices and Clinics & Others (Military, Correctional Facilities, Chronic Care Homes, and Others) based on application.

• Hospitals: Hospitals represent the largest application segment in the Latent TB Infection Testing Market Size, accounting for approximately 45% of total testing demand. Hospitals conduct latent TB infection screening among patients undergoing immunosuppressive treatments, Car evaluations, respiratory assessments, and occupational healthcare programs. Approximately 65% of tertiary hospitals utilize IGRA testing because of access to advanced laboratories and trained healthcare professionals. Hospitals also conduct routine screening among healthcare workers, who represent nearly 20% of latent TB testing activities. Early identification of latent infections helps reduce tuberculosis transmission within healthcare environments.

• Public and Student Health: Public and student health programs account for approximately 35% of latent TB infection testing applications. Government health departments, educational institutions, and community screening programs use TST and IGRA methods to identify tuberculosis exposure among large populations. Student health screening represents an important application because educational environments involve close-contact settings. Approximately 25% of public health-related latent TB tests are conducted among students, healthcare trainees, and international education populations. Universities and schools frequently require TB screening before enrollment, especially for individuals from high-prevalence regions.

• Physician Offices and Clinics: Physician offices and clinics contribute approximately 20% of the Latent TB Infection Testing Market Share due to increasing outpatient screening activities. These facilities perform testing for occupational requirements, immigration evaluations, preventive healthcare visits, and patient risk assessments. Approximately 55% of clinic-based testing involves healthcare workers, travelers, immigrants, and individuals requiring medical clearance documentation. Clinics prefer diagnostic solutions that provide accurate results with simplified workflows and minimal equipment requirements.

MARKET DYNAMICS

Driving Factor

Rising global tuberculosis prevention initiatives and increased screening programs.

The increasing focus on tuberculosis elimination programs is the primary factor supporting Latent TB Infection Testing Market Growth. Governments and healthcare organizations are expanding screening activities because approximately 25% of the global population has been exposed to tuberculosis bacteria, creating a large requirement for preventive diagnosis. More than 1.7 billion people worldwide are estimated to carry latent TB infection, increasing demand for reliable testing methods. Healthcare workers, individuals living in high-risk regions, and immunocompromised patients require regular screening to prevent disease activation. Approximately 80% of tuberculosis cases in low-incidence countries are associated with reactivation of latent infections, making early identification essential. The adoption of IGRA technologies has increased because they provide higher specificity, especially among vaccinated populations. The Latent TB Infection Testing Market Insights indicate that national TB control programs, occupational health screening, and preventive healthcare initiatives continue driving demand for advanced diagnostic solutions.

RESTRAINING FACTORS

Limited access to diagnostic infrastructure and testing affordability challenges.

Despite increasing demand, several factors restrict the expansion of the Latent TB Infection Testing Industry Analysis. Limited laboratory infrastructure affects approximately 35% of healthcare facilities in developing regions, reducing access to advanced diagnostic testing. IGRA tests require specialized laboratory equipment, trained personnel, and controlled processing environments, creating challenges in remote areas. Approximately 30% of healthcare centers in low-resource regions depend primarily on Tuberculin Skin Test methods due to lower operational requirements. Diagnostic costs remain a concern, influencing nearly 25% of healthcare providers when selecting testing approaches. Additionally, awareness limitations affect approximately 22% of high-risk populations, resulting in lower screening participation. Transportation barriers and delayed healthcare access further impact testing rates in rural communities. The Latent TB Infection Testing Market Analysis identifies infrastructure improvement and affordable diagnostic solutions as important requirements for broader market penetration.

Expansion of advanced IGRA testing and preventive healthcare screening.

Opportunity

The growing adoption of advanced immunological testing creates significant opportunities within the Latent TB Infection Testing Market Opportunities. IGRA technology is increasingly replacing traditional screening methods because of improved specificity and faster processing. Approximately 60% of healthcare providers prefer IGRA testing for populations where Tuberculin Skin Test limitations exist. Increased screening among immigrants, healthcare workers, and immunocompromised patients provides additional opportunities for diagnostic manufacturers. More than 100 countries operate national tuberculosis control programs, creating demand for scalable testing solutions. Digital healthcare integration is another opportunity area, with approximately 40% of modern laboratories adopting automated reporting systems. Portable diagnostic technologies could improve access in remote regions where laboratory infrastructure remains limited. The Latent TB Infection Testing Market Outlook highlights opportunities in developing countries through expanded healthcare networks, improved laboratory capabilities, and public-private partnerships.

Diagnostic complexity, regulatory requirements, and skilled workforce limitations.

Challenge

The Latent TB Infection Testing Market Research Report identifies operational complexity as a major challenge affecting market expansion. Advanced diagnostic testing requires trained laboratory professionals, quality control procedures, and standardized workflows. Approximately 30% of healthcare facilities in emerging regions experience shortages of trained diagnostic personnel. IGRA testing requires controlled laboratory conditions, which can be difficult to maintain in remote locations. Regulatory approval processes also influence product development timelines, with diagnostic manufacturers requiring extensive validation studies before commercialization. Approximately 25% of new diagnostic technologies face delays due to regulatory and quality compliance requirements. Supply chain challenges affecting laboratory reagents and testing materials impact nearly 18% of healthcare providers in underserved regions. Additionally, maintaining consistent test accuracy requires strict temperature control and laboratory management systems. These challenges encourage companies to develop simplified, automated, and accessible latent TB infection testing technologies.

•   
•   
  Download Free Sample to learn more about this report

    

LATENT TB INFECTION TESTING MARKET REGIONAL INSIGHTS

• North America

North America represents approximately 27% of the global Latent TB Infection Testing Market Share, supported by advanced healthcare systems, strong screening programs, and high adoption of IGRA technologies. The United States contributes nearly 80% of regional demand due to comprehensive tuberculosis monitoring programs and increased screening among high-risk groups. The region performs millions of tuberculosis-related diagnostic procedures annually, with approximately 60% of latent TB tests conducted using IGRA methods. Healthcare workers, immigrants, correctional facility populations, and immunocompromised patients represent major testing groups.

Approximately 13 million people in the United States are estimated to have latent TB infection, creating significant demand for preventive diagnosis. Nearly 80% of active tuberculosis cases in the country result from reactivation of latent infections, highlighting the importance of early detection. Canada contributes approximately 15% of North American testing demand due to immigration screening and public health programs. The region continues investing in automated laboratory systems, with approximately 45% of advanced diagnostic facilities using digital reporting technologies.

• Europe

Europe represents approximately 21% of the global Latent TB Infection Testing Market Share, supported by structured tuberculosis prevention programs, advanced healthcare infrastructure, and increasing adoption of Interferon-Gamma Release Assay (IGRA) technologies. Countries including Germany, the United Kingdom, France, Italy, Spain, and the Netherlands contribute significantly to regional testing demand. Approximately 75% of European countries operate national tuberculosis control programs that include latent TB infection screening among high-risk populations.

The European healthcare system increasingly prefers IGRA-based testing because of improved specificity compared with traditional Tuberculin Skin Test methods. Approximately 65% of latent TB infection tests conducted in Western European countries use IGRA technologies due to their ability to reduce false-positive results among BCG-vaccinated individuals. Healthcare workers, immigrants, prisoners, and immunocompromised patients represent nearly 60% of regional screening activities.

• Asia-Pacific

Asia-Pacific dominates the global Latent TB Infection Testing Market Size, accounting for approximately 42% of total testing activities due to the region’s high tuberculosis burden, large population base, and expanding healthcare programs. Countries including China, India, Indonesia, Japan, South Korea, and the Philippines represent major contributors to regional demand. The region contains several countries with high tuberculosis prevalence, creating significant demand for latent infection identification. Approximately 60% of global tuberculosis cases occur within the Asia-Pacific region, increasing the importance of preventive screening strategies. India and China collectively contribute nearly 45% of regional latent TB testing requirements.

India represents one of the largest markets, supported by national tuberculosis elimination initiatives and expanded diagnostic infrastructure. More than 1.4 billion people live in India, creating substantial screening requirements among healthcare workers, household contacts, and high-risk populations. Approximately 35% of Asia-Pacific latent TB testing activities are associated with India. China contributes approximately 30% of regional demand due to large-scale public health programs and advanced healthcare facilities. The country has increased adoption of IGRA technologies, particularly in hospitals and urban diagnostic centers. Approximately 50% of tertiary hospitals in major Chinese cities utilize advanced immunological testing methods.

• Middle East & Africa

The Middle East & Africa region contributes approximately 10% of the global Latent TB Infection Testing Market Share, with demand influenced by tuberculosis prevalence, healthcare development programs, migration patterns, and increasing public health investments. Countries including South Africa, Saudi Arabia, Egypt, Nigeria, and the United Arab Emirates represent important regional markets.

Africa accounts for a significant portion of global tuberculosis cases, creating strong demand for latent infection screening programs. Approximately 25% of global tuberculosis-related health challenges occur in African countries, increasing the need for preventive diagnosis. South Africa represents nearly 35% of regional latent TB testing activities due to high screening requirements and advanced tuberculosis control programs.

List of Top Latent TB Infection Testing Companies

• Endo International plc (Par Sterile Products, LLC/JHP Pharmaceuticals, LLC) (Ireland)
• Pharmstandard (Generium Pharmaceutical) (Russia)
• Sanofi S.A./Sanofi Pasteur Ltd. (France)
• Statens Serum Institut (SSI) (Denmark)
• Autoimmun Diagnostika (AID) GmbH (Germany)
• Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. (China)
• Haikou VTI Biological Institute (Vaccine Technologies, Inc.) (China)
• Immunoshop India Pvt. Ltd. (India)
• Qiagen N.V. (U.S.)
• Quest Diagnostics, Inc. (Oxford Immunotec Global plc) (U.S.)
• SD Biosensor, Inc. (South Korea)

TOP 2 COMPANIES WITH HIGHEST MARKET SHARE

• Qiagen N.V.: Qiagen N.V. is among the leading companies in the Latent TB Infection Testing Market, particularly through its advanced Interferon-Gamma Release Assay (IGRA) diagnostic solutions.
• Quest Diagnostics, Inc. (Oxford Immunotec Global plc): Quest Diagnostics, through its association with Oxford Immunotec Global plc, represents another major participant in the Latent TB Infection Testing Market Analysis, holding approximately 15% share in advanced latent TB diagnostic applications.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Latent TB Infection Testing Market Opportunities are increasing due to rising healthcare investments, tuberculosis elimination initiatives, and growing demand for accurate preventive diagnostics. Approximately 60% of healthcare systems worldwide are strengthening infectious disease monitoring programs, creating opportunities for diagnostic technology providers. Investments are increasingly directed toward IGRA technologies, automated laboratory platforms, and digital reporting systems. Nearly 45% of diagnostic development activities focus on improving testing speed, accuracy, and workflow efficiency. Portable and decentralized testing solutions represent another opportunity, particularly in regions where approximately 35% of healthcare facilities lack advanced laboratory infrastructure.

Emerging markets in Asia-Pacific and Africa provide significant opportunities due to expanding healthcare access. Approximately 50% of future diagnostic infrastructure investments are expected to focus on improving tuberculosis screening availability in developing regions. Pharmaceutical and biotechnology collaborations are also increasing, supporting innovation in tuberculosis prevention strategies. Around 30% of healthcare technology investments involve partnerships between diagnostic companies, research institutions, and public health organizations.Next

NEW PRODUCT DEVELOPMENT

The Latent TB Infection Testing Market is witnessing continuous product development focused on improving diagnostic accuracy, reducing testing time, and increasing accessibility across healthcare systems. Approximately 45% of newly developed latent TB diagnostic solutions focus on improving Interferon-Gamma Release Assay (IGRA) performance, while nearly 30% emphasize automation and digital integration. Manufacturers are developing advanced testing platforms capable of processing higher sample volumes, reducing laboratory workload by approximately 25%, and improving result management through electronic reporting systems.

New-generation IGRA platforms are being designed with enhanced sensitivity and specificity features to support high-risk population screening. Approximately 60% of product innovation activities focus on improving detection reliability among healthcare workers, immunocompromised patients, and individuals from high tuberculosis prevalence regions. Companies are also developing simplified diagnostic systems requiring fewer laboratory steps, enabling adoption in healthcare facilities with limited technical resources. Portable latent TB infection testing technologies represent another important innovation area. Approximately 20% of research and development programs focus on compact diagnostic solutions that can operate in community healthcare settings. These technologies aim to improve access in rural regions where approximately 35% of healthcare facilities face laboratory infrastructure limitations.

FIVE RECENT DEVELOPMENTS (2023-2025)

• March 2023: Qiagen N.V. expanded a new initiative related to the Latent TB Infection Testing Market by enhancing its QuantiFERON tuberculosis diagnostic solutions. The company focused on improving laboratory workflow efficiency, automation compatibility, and digital connectivity for latent TB screening applications. The initiative supported hospitals, reference laboratories, and public health programs by enabling faster processing, improved test management, and broader adoption of advanced Interferon-Gamma Release Assay (IGRA) technologies.
• September 2023: SD Biosensor, Inc. introduced a new initiative related to the Latent TB Infection Testing Market by advancing its immunodiagnostic technology portfolio for infectious disease screening. The development focused on improving assay performance, simplifying diagnostic procedures, and expanding accessibility in healthcare facilities. The innovation supported emerging markets by providing scalable testing approaches designed for efficient tuberculosis screening and improved disease prevention strategies.
• May 2024: Quest Diagnostics, Inc. expanded a new initiative related to the Latent TB Infection Testing Market through enhanced laboratory-based tuberculosis screening services. The company invested in digital diagnostic integration, streamlined reporting systems, and improved testing accessibility for healthcare providers. The expansion strengthened occupational health, hospital, and public health screening capabilities while supporting faster communication of latent TB infection test results.
• October 2024: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. developed a new initiative related to the Latent TB Infection Testing Market by advancing tuberculosis diagnostic research and immunological testing technologies. The company focused on improving assay reliability, laboratory efficiency, and diagnostic accessibility across high-burden regions. The initiative supported healthcare systems seeking accurate screening solutions and strengthened the company’s position in infectious disease diagnostics.
• January 2025: Autoimmun Diagnostika (AID) GmbH launched a new initiative related to the Latent TB Infection Testing Market by introducing laboratory optimization improvements for immunodiagnostic workflows. The development emphasized automation, quality control enhancement, and efficient interpretation processes for tuberculosis testing applications. The initiative aimed to improve diagnostic consistency, reduce manual workload, and support laboratories managing increasing latent TB infection screening requirements.

REPORT COVERAGE OF LATENT TB INFECTION TESTING MARKET

The Latent TB Infection Testing Market Report provides comprehensive analysis of diagnostic technologies, applications, regional performance, competitive landscape, product innovation, and industry opportunities. The report evaluates major testing methods including Mantoux Test / Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (IGRA), which collectively represent approximately 100% of global latent TB diagnostic approaches. The report examines application segments including hospitals, public and student health programs, and physician offices and clinics. Hospitals account for approximately 45% of market utilization, while public health programs contribute nearly 35% and physician offices represent approximately 20% of testing activities.

Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa. Asia-Pacific represents approximately 42% of testing demand due to higher tuberculosis prevalence, while North America contributes nearly 27% through advanced healthcare infrastructure and diagnostic adoption. The Latent TB Infection Testing Market Analysis evaluates industry drivers, restraints, opportunities, and challenges influencing market development. Key factors assessed include increasing tuberculosis screening programs, healthcare infrastructure expansion, diagnostic technology improvements, and demand for accurate preventive testing.